TriSalus Life Sciences (TLSI) Stock Analysis & AI Equity Report
TriSalus Life Sciences (TLSI) overview
TriSalus Life Sciences (TLSI) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 45.2m and operating profit of USD -26.9m; the year-end share price was 6.98 USD and market capitalisation was USD 349m. TriSalus Life Sciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get TriSalus Life Sciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About TriSalus Life Sciences
TriSalus Life Sciences develops medical technology and investigational therapies for solid tumors. Its Pressure-Enabled Drug Delivery technology is designed to improve delivery of therapeutics into tumors by modulating pressure and blood vessel flow. Its TriNav Infusion System is used in interventional radiology procedures, including treatment of primary liver cancer and liver metastases. The company develops nelitolimod, an investigational immunotherapeutic, and devices for pancreatic tumor infusions.
Generate the TriSalus Life Sciences report
TriSalus Life Sciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for TriSalus Life Sciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on TriSalus Life Sciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.